Global Antibody Drug Conjugates Market to Reach US$ 22.4 Billion by 2028, Impelled by Increasing Instances of Cancer

December 10, 2021 | Healthcare

According to the latest report by IMARC Group, titled “Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global antibody drug conjugates market reached a value of US$ 6.3 Billion in 2022. Antibody drug conjugates (ADCs) refer to a class of biopharmaceutical drugs that are designed as a targeted therapy for treating cancer. They are made up of monoclonal antibodies (mAb) that chemically bind to specific receptors or proteins found on cancer cells. Upon entering the cells, the linked cytotoxic anticancer agents trigger the internalization of the antibody and allows sensitive bifurcation between healthy and diseased tissues. This, in turn, assists in enhancing the cell-killing potential of mAb, increasing drug tolerability, maximizing efficiency, and minimizing systematic exposure.

Global Antibody Drug Conjugates Market Trends:

The global ADCs market is majorly being driven by the increasing prevalence of cancer due to sedentary lifestyle and rising number of smokers. In confluence with this, the shifting individual preference toward targeted and personalized cancer treatments is further facilitating the need for ADCs across the globe. Additionally, rising healthcare expenditures, along with rapid advancements in medical technologies to engineer novel linkers with additional antibody attachments to allow the expansion of payloads are acting as other growth-inducing factor. Furthermore, manufacturers are continuously investing in research and development (R&D) activities to optimize existing chemical triggers and improve the absorption, distribution, metabolism, and excretion, which are catalyzing the market growth. Other than this, vendors are increasingly collaborating with other companies to share resources, technology, product knowledge, and expand businesses. For instance, in 2019, Shanghai Miracogen entered into an agreement with Netherlands-based Synaffix to utilize its tools and resources for building ADCs. This, in turn, is creating a positive outlook for the market. Looking forward, the market is expected to reach a value of US$ 22.4 Billion by 2028, exhibiting a CAGR of 23.35% during 2023-2028.

Market Summary:

Based on the component, the market has been divided into monoclonal antibodies, linker, cytotoxic agent, and others.
On the basis of the target, the market has been classified into antibody-protein toxin, antibody-chelated radionuclide, antibody-small-molecule drug, and antibody-enzyme conjugates.
Based on the application, the market has been segmented into lymphoma, ovarian cancer, lung cancer, breast cancer, brain tumor, and others.
On the basis of the end user, the market has been divided into hospitals, specialized cancer centers, academic research institutes, biotechnology companies, and others.
On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
The competitive landscape of the market has also been examined, with some of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Report Scope:

Report Features	Details
Base Year of the Analysis	2022
Historical Period	2017-2022
Forecast Period	2023-2028
Units	US$ Billion
Segment Coverage	Component, Target, Application, End User, Region
Region Covered	Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered	United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered	ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.
Customization Scope	10% Free Customization
Report Price and Purchase Option	Single User License: US$ 2499 Five User License: US$ 3499 Corporate License: US$ 4499
Post-Sale Analyst Support	10-12 Weeks
Delivery Format	PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
USA: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter : @imarcglobal

Need more help?

Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.

Global Antibody Drug Conjugates Market to Reach US$ 22.4 Billion by 2028, Impelled by Increasing Instances of Cancer

Purchase options Year End sale

Single User License ~~$2499~~ $2249
Five User License ~~$3499~~ $2974
Corporate License ~~$4499~~ $3599

Inquire Before Buying

Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Speak to an Analyst

Request Brochure

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.